Revolutionizing Biotechnology

 SVAX, a pioneering force in the halal vaccines field, has recently expanded its focus to include biologics, aligning with broader market trends towards vegan and Halal products. Co-Founder and Managing Director Prof. Mazen M. Hassanain outlines how the company has shifted its distributor strategy to form partnerships with small to medium-sized biotech firms, particularly in regions outside traditional pharmaceutical hubs, and is continuing to leverage its scientific expertise for commercial success and improved patient access. 

At the HealthTech Summit & Expo, Prof. Mazen Hassanain delivered an insightful session on the future of biotechnology in Saudi Arabia. Highlighting key trends, advancements, and breakthroughs, he discussed the growing role of biotechnology in transforming the Kingdom's healthcare landscape. Dr. Hassanain's presentation explored the exciting potential of biotechnological innovations and how they are shaping Saudi Arabia's future in the global biotech arena.

In alignment with Vision 2030 and Saudi Arabia’s National Biotech Strategy, the Kingdom is embarking on a transformative journey to localize the product and clinical development value chain. This bold move is set to position Saudi Arabia as a leader in the global biotech and pharmaceutical industries, fostering economic growth, advancing healthcare innovation, and creating high-value job opportunities.

Saudi Arabia’s National Biotechnology Strategy is a transformative initiative that aims to position the Kingdom as a global leader in biotechnology by 2040. Focused on healthcare innovation, environmental sustainability, economic growth, and food security, this strategy is a cornerstone of Vision 2030, driving localization, self-sufficiency, and global competitiveness across multiple sectors.

Under the leadership of #Vision2030, Saudi Arabia is rapidly becoming a global hub for innovation and investment in the biotechnology sector. The Kingdom's National Biotech Strategy is a bold step forward to transform the healthcare landscape by investing in a robust biotech ecosystem and localizing the entire biologics development value chain.